InSitu Biologics has continued to make great strides over the past few months. We have successfully submitted our Pre-IND application to the FDA, as well as applied […]
InSitu Biologics has continued to make great strides over the past few months. We have successfully submitted our Pre-IND application to the FDA, as well as applied […]
Our Regulation A+ Offering is now officially closed. Please continue to follow our progress here on our site, on social media, or via newsletter. Thank you.
Insitu Biologics continues to make rapid progress towards our mission of providing patients and physicians with an opioid-free solution for post-operative pain. We have added exceptional talent […]
We have received a tremendous amount of interest in this last tier and have also received requests to hold the offering open longer to allow numerous interested […]
Our Biotech Investor Presentation is TONIGHT! As our Regulation A+ offering is coming to a close, we invite you to join us for an investor presentation […]
The Financial Opportunity As many of you know, post-operative pain treatment is dominated by opiates, with 95% of patients receiving opiates for pain management. Only one non-opioid, […]
InSitu Biologics’ co-founder and medical adviser Dan Sipple has been featured by his alma mater Des Moines University. Click here to […]
As of October 19th, our Stock Offering is once again open and accepting investments. Our plan is to close our Regulation A+ Offering for the last time […]
As of October 15, our Stock Offering is temporarily paused. During this pause, we will be taking reservations and encourage prospective investors to reserve shares via the […]
Thank you to LGM Pharma for including InSitu Biologics in a recent Client Feature! We have recently shifted management of our supply chain to LGM Pharma, including […]